Rhumbline Advisers Day One Biopharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $121 Billion
- Q3 2025
A detailed history of Rhumbline Advisers transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 121,945 shares of DAWN stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121,945
Previous 116,060
5.07%
Holding current value
$1.07 Million
Previous $754,000
13.93%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
70.5MCall Options Held
42.8KPut Options Held
60.3K-
Atlas Venture Life Science Advisors, LLC6.43MShares$56.6 Million10.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.18MShares$54.4 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.71MShares$41.4 Million0.62% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$39.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.48MShares$30.6 Million0.01% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $646M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...